Literature DB >> 22212680

Targeting proteinase-activated receptors: therapeutic potential and challenges.

Rithwik Ramachandran1, Farshid Noorbakhsh, Kathryn Defea, Morley D Hollenberg.   

Abstract

Proteinase-activated receptors (PARs), a family of four seven-transmembrane G protein-coupled receptors, act as targets for signalling by various proteolytic enzymes. PARs are characterized by a unique activation mechanism involving the proteolytic unmasking of a tethered ligand that stimulates the receptor. Given the emerging roles of these receptors in cancer as well as in disorders of the cardiovascular, musculoskeletal, gastrointestinal, respiratory and central nervous system, PARs have become attractive targets for the development of novel therapeutics. In this Review we summarize the mechanisms by which PARs modulate cell function and the roles they can have in physiology and diseases. Furthermore, we provide an overview of possible strategies for developing PAR antagonists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22212680     DOI: 10.1038/nrd3615

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  233 in total

1.  Novel agonists and antagonists for human protease activated receptor 2.

Authors:  Grant D Barry; Jacky Y Suen; Giang T Le; Adam Cotterell; Robert C Reid; David P Fairlie
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

2.  Role of the thrombin receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for agonist-triggered versus tonic internalization and intracellular localization.

Authors:  M J Shapiro; J Trejo; D Zeng; S R Coughlin
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

3.  Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs).

Authors:  Katerina Oikonomopoulou; Kristina K Hansen; Mahmoud Saifeddine; Nathalie Vergnolle; Illa Tea; Michael Blaber; Sachiko I Blaber; Isobel Scarisbrick; Eleftherios P Diamandis; Morley D Hollenberg
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

4.  Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides.

Authors:  M D Hollenberg; M Saifeddine
Journal:  Can J Physiol Pharmacol       Date:  2001-05       Impact factor: 2.273

5.  Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.

Authors:  P Andrade-Gordon; C K Derian; B E Maryanoff; H C Zhang; M F Addo; B P Damiano; M R D'Andrea; A L Darrow; L de Garavilla; A J Eckardt; E C Giardino; B J Haertlein; D F McComsey
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

6.  Protease-activated receptor 3 is a second thrombin receptor in humans.

Authors:  H Ishihara; A J Connolly; D Zeng; M L Kahn; Y W Zheng; C Timmons; T Tram; S R Coughlin
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

7.  Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis.

Authors:  Leonie A Boven; Nathalie Vergnolle; Scot D Henry; Claudia Silva; Yoshinori Imai; Janet Holden; Kenneth Warren; Morley D Hollenberg; Christopher Power
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

8.  Relative importance of proteinase-activated receptor-1 versus matrix metalloproteinases in intracerebral hemorrhage-mediated neurotoxicity in mice.

Authors:  Mengzhou Xue; Morley D Hollenberg; Andrew Demchuk; V Wee Yong
Journal:  Stroke       Date:  2009-04-09       Impact factor: 7.914

9.  Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.

Authors:  Yasuko Kato; Yasuhiro Kita; Yoshimi Hirasawa-Taniyama; Mie Nishio; Kayoko Mihara; Kiyotaka Ito; Toshio Yamanaka; Jiro Seki; Susumu Miyata; Seitaro Mutoh
Journal:  Eur J Pharmacol       Date:  2003-07-25       Impact factor: 4.432

10.  'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage.

Authors:  Nicole C Kaneider; Andrew J Leger; Anika Agarwal; Nga Nguyen; George Perides; Claudia Derian; Lidija Covic; Athan Kuliopulos
Journal:  Nat Immunol       Date:  2007-10-28       Impact factor: 25.606

View more
  124 in total

1.  Genetic targeting of protease activated receptor 2 reduces inflammatory astrogliosis and improves recovery of function after spinal cord injury.

Authors:  Maja Radulovic; Hyesook Yoon; Jianmin Wu; Karim Mustafa; Michael G Fehlings; Isobel A Scarisbrick
Journal:  Neurobiol Dis       Date:  2015-08-24       Impact factor: 5.996

Review 2.  Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease.

Authors:  M D Hollenberg; K Mihara; D Polley; J Y Suen; A Han; D P Fairlie; R Ramachandran
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

3.  Induction of complement C3a receptor responses by kallikrein-related peptidase 14.

Authors:  Katerina Oikonomopoulou; Robert A DeAngelis; Hui Chen; Eleftherios P Diamandis; Morley D Hollenberg; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

Review 4.  Proteinases, their receptors and inflammatory signalling: the Oxford South Parks Road connection.

Authors:  M D Hollenberg
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

5.  Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?

Authors:  Christopher T Szlenk; Jeevan B Gc; Senthil Natesan
Journal:  Mol Pharmacol       Date:  2019-04-08       Impact factor: 4.436

6.  The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo.

Authors:  M S Grace; T Lieu; B Darby; F C Abogadie; N Veldhuis; N W Bunnett; P McIntyre
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 7.  Inflammation, obesity, and thrombosis.

Authors:  Fahumiya Samad; Wolfram Ruf
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

8.  Evaluation of antibodies directed against human protease-activated receptor-2.

Authors:  Mark N Adams; Charles N Pagel; Eleanor J Mackie; John D Hooper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-31       Impact factor: 3.000

9.  Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder.

Authors:  WooJin Kim; Erin Zekas; Robert Lodge; Delia Susan-Resiga; Edwidge Marcinkiewicz; Rachid Essalmani; Koichiro Mihara; Rithwik Ramachandran; Eugene Asahchop; Benjamin Gelman; Éric A Cohen; Christopher Power; Morley D Hollenberg; Nabil G Seidah
Journal:  Mol Cell Biol       Date:  2015-08-17       Impact factor: 4.272

10.  PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo.

Authors:  R Auvergne; C Wu; A Connell; S Au; A Cornwell; M Osipovitch; A Benraiss; S Dangelmajer; H Guerrero-Cazares; A Quinones-Hinojosa; S A Goldman
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.